Kelly Legislation to Lower Drug Prices Passes Full Energy & Commerce Committee
Washington, DC – Yesterday, the House Energy and Commerce Committee advanced Congresswoman Robin Kelly’s Orange Book Transparency Act (H.R. 1503) to the full House of Representatives for consideration and action.
Introduced in March, the Orange Book Transparency Act would increase access to lower cost generic drugs and bolster competition in the marketplace to drive down prescription drug costs for American families.
“No one should be forced to choose between lifesaving medicine and putting food on the table. Sadly, this is the everyday reality of too many people,” said Congresswoman Robin Kelly, chair of the Congressional Black Caucus Health Braintrust, “There is more that we can and should do to lower drug costs for American families. This bill will increase access to and competition from generic drugs. The result will be lower out-of-pocket costs for families – a major promise of Democrats’ For the People agenda.”
Congresswoman Kelly’s legislation would make several small technical changes to the FDA’s drug product listing, the Orange Book, and its submission process to create greater clarity for doctors, pharmacists and generic drug manufacturers. Changes have been requested by experts, medical professionals and advocates for years.
The Orange Book is used by doctors and pharmacists for information on generic drug approvals and availability. It is also used by generic drug manufacturers to make critical R&D decisions, as it provides information on the exclusivity period of novel, name-brand drugs.
The legislation was favorably reported by the health subcommittee, on which Rep. Kelly serves, on March 27th.
Note: The House Energy and Commerce Committee is the oldest continuously standing committee in Congress; it was established in 1795. Today, the Committee serves as Congress’ chief policymaking body with broad jurisdiction over healthcare, energy, environmental, consumer safety and electronic communication policy.